$GILD News Cy
Post# of 44872
Posted On: 12/08/2014 12:19:45 PM
$GILD News
Cypress, Spansion shares rally on merger plan
5:36 p.m. Dec. 1, 2014
- MarketWatch
Mylan to manufacture, distribute Gilead Sciences HIV drug
7:49 a.m. Dec. 1, 2014
- Angela Chen
10 stocks that may revisit their highs as the year ends
10:30 a.m. Nov. 24, 2014
- Philip van Doorn
Are consumers getting gouged on health care?
9:35 a.m. Nov. 22, 2014
- Russ Britt
Gilead Sciences shares slide 1.7%
9:35 a.m. Nov. 19, 2014
- Sue Chang
The double-edged sword of growth-stock speculation
2:29 p.m. Nov. 14, 2014
- The Trading Deck
10 S&P 500 companies with the fastest revenue growth
8:28 a.m. Nov. 11, 2014
- Philip van Doorn
Merck, Dendreon miss out on health-care rally
12:39 p.m. Nov. 10, 2014
- Russ Britt
Gilead Sciences rises 2% to top S&P 500 gainers
9:31 a.m. Nov. 10, 2014
- Sue Chang
Visa shares rise after hours on earnings beat
6:50 p.m. Oct. 29, 2014
- Sue Chang
Warren Buffett best wear his trunks as Fed preps to end (pause) the printing
8:34 a.m. Oct. 29, 2014
- Shawn Langlois
Facebook, Gilead shares fall after hours
6:14 p.m. Oct. 28, 2014
- Sue Chang
Updates, advisories and surprises
5:01 p.m. Oct. 28, 2014
- MarketWatch
Sales of Gilead's pricey hepatitis C drug slow
4:26 p.m. Oct. 28, 2014
- MarketWatch.com
Gilead Sciences' stock pulls back from record high close after earnings miss
4:14 p.m. Oct. 28, 2014
- Tomi Kilgore
Gilead's stock drops 3.6% in after-hours trade after Q3 results
4:09 p.m. Oct. 28, 2014
- Tomi Kilgore
Gilead revises 2014 product sales outlook to $22 bln-$23 bln from $21 bln-$23 bln
4:08 p.m. Oct. 28, 2014
- Tomi Kilgore
Gilead Q3 Sovaldi sales $2.8 bln vs. $3.48 bln in Q2
4:07 p.m. Oct. 28, 2014
- Tomi Kilgore
Gilead Q3 sales top FactSet consensus estimate of $5.99 bln
4:07 p.m. Oct. 28, 2014
- Tomi Kilgore
Gilead Q3 sales $6.04 bln vs. $2.78 bln a year ago
4:07 p.m. Oct. 28, 2014
- Tomi Kilgore
Drug Stocks Rally But Falling Crude and Energy Stocks Weigh on S&P 500
40 min ago11:39 a.m. Dec. 8, 2014
- TheStreet.com
Stocks Near Flatline as Rally in Pharmaceuticals Overshadows Energy Selloff
11:04 a.m. Today11:04 a.m. Dec. 8, 2014
- TheStreet.com
2 Core Holdings That Belong In Every Biotech Portfolio
9:45 a.m. Today9:45 a.m. Dec. 8, 2014
- Seeking Alpha
A Comprehensive Comparison Of Gilead's Harvoni And AbbVie's Triple HCV Regimen: What The HCV Marketplace May Look Like In 2015 And Beyond
9:23 a.m. Today9:23 a.m. Dec. 8, 2014
- Seeking Alpha
Cramer's Mad Money - Ulta Salon Is Looking Good (12/5/14)
5:43 a.m. Today5:43 a.m. Dec. 8, 2014
- Seeking Alpha
Best Janus Funds to Buy for 2015
12:01 a.m. Today12:01 a.m. Dec. 8, 2014
- InvestorPlace.com
Health and Tech Funds Step Up
11:06 p.m. Dec. 7, 2014
- The Wall Street Journal Interactive Edition
Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
8:22 p.m. Dec. 5, 2014
- TheStreet.com
Why Gilead Is A Better Buy Than AbbVie
2:52 p.m. Dec. 5, 2014
- Seeking Alpha
Cramer Says It May Finally Be Time to Buy Laggard Gilead Sciences
12:18 p.m. Dec. 5, 2014
- TheStreet.com
Gilead Sciences Spikes Higher As Barron's Suggests Looking Beyond Hepatitis-C
9:50 a.m. Dec. 5, 2014
- benzinga.com
'Mad Money' Lightning Round: Buy, Buy, Buy Texas Instruments
6:00 a.m. Dec. 5, 2014
- TheStreet.com
Cramer's Lightning Round - Constellation Brands Has Real Magic (12/4/14)
4:36 a.m. Dec. 5, 2014
- Seeking Alpha
Jim Cramer's 'Mad Money' Recap: Google Is Better Than the Market Thinks
8:31 p.m. Dec. 4, 2014
- TheStreet.com
Hot Drugmakers Build More Labs, Grab Space In Boston
3:47 p.m. Dec. 4, 2014
- Investors Business Daily
Gilead Sciences: An Alpha Stock Through The Good And Bad Times
3:14 p.m. Dec. 4, 2014
- Seeking Alpha
A Practical Approach To Tech Investing
9:00 a.m. Dec. 4, 2014
- Seeking Alpha
U.S. Veterans get Sovaldi for $594/pill
8:43 a.m. Dec. 4, 2014
- Seeking Alpha
Cramer's Mad Money - PVH Fits Well At A Discount (12/3/14)
6:04 a.m. Dec. 4, 2014
- Seeking Alpha
Jim Cramer's 'Mad Money' Recap: Cyclical Stocks Are Fund Manager Picks Now
8:36 p.m. Dec. 3, 2014
- TheStreet.com
Gilead Presents Follow-up Data from Zydelig Registrational Studies in
Patients with Chronic Lymphocytic Leukemia, Follicular Lymphoma and
Small Lymphocytic Lymphoma
10:00 a.m. Today10:00 a.m. Dec. 8, 2014
- BusinessWire - BZX
Reveal Earnings Forecast for Gilead Sciences, Apple, Transocean, Halliburton, Ctrip, and Sirius XM
8:45 a.m. Today8:45 a.m. Dec. 8, 2014
- PR Newswire - PRF
Reveal Earnings Forecast for Gilead Sciences, Kinder Morgan, JD.Com, Sirius XM, Apple, and Plug Power
8:45 a.m. Dec. 4, 2014
- PR Newswire - PRF
Earnings Forecast Reports for Apple, Alibaba, Kinder Morgan, Gilead Sciences, Plug Power, and Yahoo
8:45 a.m. Dec. 2, 2014
- PR Newswire - PRF
Mylan Signs Agreement with Gilead to Enhance Access to Tenofovir Alafenamide (TAF)-based HIV Treatments in Developing Countries
7:00 a.m. Dec. 1, 2014
- PR Newswire - PRF
Reveal Earnings Forecast for Apple, Alibaba, Hewlett-Packard, Gilead Sciences, Petrobras, and BlackBerry
8:45 a.m. Nov. 26, 2014
- PR Newswire - PRF
Critical Alerts For SouFun, Petroleo Brasileiro, Gilead Sciences, Transocean and iRobot Released By InvestorsObserver
9:31 a.m. Nov. 24, 2014
- PR Newswire - PRF
Earnings Forecast Research for Kinder Morgan, Petrobras, Freeport-McMoRan, Keurig Green Mountain, Gilead Sciences, and Alibaba
8:45 a.m. Nov. 24, 2014
- PR Newswire - PRF
Earnings Forecast Report for Yahoo, Alibaba, Cliffs Natural Resources, Gilead Sciences, Apple, and Plug Power
8:45 a.m. Nov. 20, 2014
- PR Newswire - PRF
Knight Sells Priority Review Voucher to Gilead
5:11 p.m. Nov. 19, 2014
- Marketwired
European Commission Grants Marketing Authorization for Gilead’s
Harvoni®▼ (Ledipasvir/Sofosbuvir), the First
Single Tablet Regimen to Treat the Majority of Chronic Hepatitis C
Patients With Genotype 1 and 4
10:07 a.m. Nov. 18, 2014
- BusinessWire - BZX
Earnings Forecast Buzz for Baker Hughes, Halliburton, Apple, Gilead Sciences, Kinder Morgan, and Alibaba
8:45 a.m. Nov. 18, 2014
- PR Newswire - PRF
Equity Coverage on Biotech Industry - Gilead Sciences, MannKind, ARIAD Pharma, iBio Inc., and Celgene
9:10 a.m. Nov. 14, 2014
- PR Newswire - PRF
Reveal Earnings Forecast for BlackBerry, Twitter, Alibaba, Sirius XM, Gilead Sciences, and JD.Com
8:45 a.m. Nov. 14, 2014
- PR Newswire - PRF
Gilead Prices $4 Billion of Senior Unsecured Notes
5:59 p.m. Nov. 12, 2014
- BusinessWire - BZX
Earnings Forecast Recap for Alibaba, Apple, Zynga, Gilead Sciences, Dendreon, and Juniper
8:45 a.m. Nov. 12, 2014
- PR Newswire - PRF
Gilead Announces Phase 2 Data for Investigational All-Oral Regimen of
Sofosbuvir Plus GS-5816 for the Treatment of Chronic Hepatitis C
8:02 a.m. Nov. 11, 2014
- BusinessWire - BZX
Gilead Announces Harvoni Study Results in Chronic Hepatitis C
Patients with Advanced Liver Disease and Those Who Failed Prior Treatment
8:02 a.m. Nov. 11, 2014
- BusinessWire - BZX
Earnings Forecast Buzz for Alibaba, Genworth Financial, Gilead Sciences, Zynga, Abercrombie & Fitch, and Plug Power
8:45 a.m. Nov. 10, 2014
- PR Newswire - PRF
Medifocus to Be Broadcast on BNN and Fox Business News on November
8th and 9th, 2014
10:56 a.m. Nov. 7, 2014
- Marketwired
Cypress, Spansion shares rally on merger plan
5:36 p.m. Dec. 1, 2014
- MarketWatch
Mylan to manufacture, distribute Gilead Sciences HIV drug
7:49 a.m. Dec. 1, 2014
- Angela Chen
10 stocks that may revisit their highs as the year ends
10:30 a.m. Nov. 24, 2014
- Philip van Doorn
Are consumers getting gouged on health care?
9:35 a.m. Nov. 22, 2014
- Russ Britt
Gilead Sciences shares slide 1.7%
9:35 a.m. Nov. 19, 2014
- Sue Chang
The double-edged sword of growth-stock speculation
2:29 p.m. Nov. 14, 2014
- The Trading Deck
10 S&P 500 companies with the fastest revenue growth
8:28 a.m. Nov. 11, 2014
- Philip van Doorn
Merck, Dendreon miss out on health-care rally
12:39 p.m. Nov. 10, 2014
- Russ Britt
Gilead Sciences rises 2% to top S&P 500 gainers
9:31 a.m. Nov. 10, 2014
- Sue Chang
Visa shares rise after hours on earnings beat
6:50 p.m. Oct. 29, 2014
- Sue Chang
Warren Buffett best wear his trunks as Fed preps to end (pause) the printing
8:34 a.m. Oct. 29, 2014
- Shawn Langlois
Facebook, Gilead shares fall after hours
6:14 p.m. Oct. 28, 2014
- Sue Chang
Updates, advisories and surprises
5:01 p.m. Oct. 28, 2014
- MarketWatch
Sales of Gilead's pricey hepatitis C drug slow
4:26 p.m. Oct. 28, 2014
- MarketWatch.com
Gilead Sciences' stock pulls back from record high close after earnings miss
4:14 p.m. Oct. 28, 2014
- Tomi Kilgore
Gilead's stock drops 3.6% in after-hours trade after Q3 results
4:09 p.m. Oct. 28, 2014
- Tomi Kilgore
Gilead revises 2014 product sales outlook to $22 bln-$23 bln from $21 bln-$23 bln
4:08 p.m. Oct. 28, 2014
- Tomi Kilgore
Gilead Q3 Sovaldi sales $2.8 bln vs. $3.48 bln in Q2
4:07 p.m. Oct. 28, 2014
- Tomi Kilgore
Gilead Q3 sales top FactSet consensus estimate of $5.99 bln
4:07 p.m. Oct. 28, 2014
- Tomi Kilgore
Gilead Q3 sales $6.04 bln vs. $2.78 bln a year ago
4:07 p.m. Oct. 28, 2014
- Tomi Kilgore
Drug Stocks Rally But Falling Crude and Energy Stocks Weigh on S&P 500
40 min ago11:39 a.m. Dec. 8, 2014
- TheStreet.com
Stocks Near Flatline as Rally in Pharmaceuticals Overshadows Energy Selloff
11:04 a.m. Today11:04 a.m. Dec. 8, 2014
- TheStreet.com
2 Core Holdings That Belong In Every Biotech Portfolio
9:45 a.m. Today9:45 a.m. Dec. 8, 2014
- Seeking Alpha
A Comprehensive Comparison Of Gilead's Harvoni And AbbVie's Triple HCV Regimen: What The HCV Marketplace May Look Like In 2015 And Beyond
9:23 a.m. Today9:23 a.m. Dec. 8, 2014
- Seeking Alpha
Cramer's Mad Money - Ulta Salon Is Looking Good (12/5/14)
5:43 a.m. Today5:43 a.m. Dec. 8, 2014
- Seeking Alpha
Best Janus Funds to Buy for 2015
12:01 a.m. Today12:01 a.m. Dec. 8, 2014
- InvestorPlace.com
Health and Tech Funds Step Up
11:06 p.m. Dec. 7, 2014
- The Wall Street Journal Interactive Edition
Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
8:22 p.m. Dec. 5, 2014
- TheStreet.com
Why Gilead Is A Better Buy Than AbbVie
2:52 p.m. Dec. 5, 2014
- Seeking Alpha
Cramer Says It May Finally Be Time to Buy Laggard Gilead Sciences
12:18 p.m. Dec. 5, 2014
- TheStreet.com
Gilead Sciences Spikes Higher As Barron's Suggests Looking Beyond Hepatitis-C
9:50 a.m. Dec. 5, 2014
- benzinga.com
'Mad Money' Lightning Round: Buy, Buy, Buy Texas Instruments
6:00 a.m. Dec. 5, 2014
- TheStreet.com
Cramer's Lightning Round - Constellation Brands Has Real Magic (12/4/14)
4:36 a.m. Dec. 5, 2014
- Seeking Alpha
Jim Cramer's 'Mad Money' Recap: Google Is Better Than the Market Thinks
8:31 p.m. Dec. 4, 2014
- TheStreet.com
Hot Drugmakers Build More Labs, Grab Space In Boston
3:47 p.m. Dec. 4, 2014
- Investors Business Daily
Gilead Sciences: An Alpha Stock Through The Good And Bad Times
3:14 p.m. Dec. 4, 2014
- Seeking Alpha
A Practical Approach To Tech Investing
9:00 a.m. Dec. 4, 2014
- Seeking Alpha
U.S. Veterans get Sovaldi for $594/pill
8:43 a.m. Dec. 4, 2014
- Seeking Alpha
Cramer's Mad Money - PVH Fits Well At A Discount (12/3/14)
6:04 a.m. Dec. 4, 2014
- Seeking Alpha
Jim Cramer's 'Mad Money' Recap: Cyclical Stocks Are Fund Manager Picks Now
8:36 p.m. Dec. 3, 2014
- TheStreet.com
Gilead Presents Follow-up Data from Zydelig Registrational Studies in
Patients with Chronic Lymphocytic Leukemia, Follicular Lymphoma and
Small Lymphocytic Lymphoma
10:00 a.m. Today10:00 a.m. Dec. 8, 2014
- BusinessWire - BZX
Reveal Earnings Forecast for Gilead Sciences, Apple, Transocean, Halliburton, Ctrip, and Sirius XM
8:45 a.m. Today8:45 a.m. Dec. 8, 2014
- PR Newswire - PRF
Reveal Earnings Forecast for Gilead Sciences, Kinder Morgan, JD.Com, Sirius XM, Apple, and Plug Power
8:45 a.m. Dec. 4, 2014
- PR Newswire - PRF
Earnings Forecast Reports for Apple, Alibaba, Kinder Morgan, Gilead Sciences, Plug Power, and Yahoo
8:45 a.m. Dec. 2, 2014
- PR Newswire - PRF
Mylan Signs Agreement with Gilead to Enhance Access to Tenofovir Alafenamide (TAF)-based HIV Treatments in Developing Countries
7:00 a.m. Dec. 1, 2014
- PR Newswire - PRF
Reveal Earnings Forecast for Apple, Alibaba, Hewlett-Packard, Gilead Sciences, Petrobras, and BlackBerry
8:45 a.m. Nov. 26, 2014
- PR Newswire - PRF
Critical Alerts For SouFun, Petroleo Brasileiro, Gilead Sciences, Transocean and iRobot Released By InvestorsObserver
9:31 a.m. Nov. 24, 2014
- PR Newswire - PRF
Earnings Forecast Research for Kinder Morgan, Petrobras, Freeport-McMoRan, Keurig Green Mountain, Gilead Sciences, and Alibaba
8:45 a.m. Nov. 24, 2014
- PR Newswire - PRF
Earnings Forecast Report for Yahoo, Alibaba, Cliffs Natural Resources, Gilead Sciences, Apple, and Plug Power
8:45 a.m. Nov. 20, 2014
- PR Newswire - PRF
Knight Sells Priority Review Voucher to Gilead
5:11 p.m. Nov. 19, 2014
- Marketwired
European Commission Grants Marketing Authorization for Gilead’s
Harvoni®▼ (Ledipasvir/Sofosbuvir), the First
Single Tablet Regimen to Treat the Majority of Chronic Hepatitis C
Patients With Genotype 1 and 4
10:07 a.m. Nov. 18, 2014
- BusinessWire - BZX
Earnings Forecast Buzz for Baker Hughes, Halliburton, Apple, Gilead Sciences, Kinder Morgan, and Alibaba
8:45 a.m. Nov. 18, 2014
- PR Newswire - PRF
Equity Coverage on Biotech Industry - Gilead Sciences, MannKind, ARIAD Pharma, iBio Inc., and Celgene
9:10 a.m. Nov. 14, 2014
- PR Newswire - PRF
Reveal Earnings Forecast for BlackBerry, Twitter, Alibaba, Sirius XM, Gilead Sciences, and JD.Com
8:45 a.m. Nov. 14, 2014
- PR Newswire - PRF
Gilead Prices $4 Billion of Senior Unsecured Notes
5:59 p.m. Nov. 12, 2014
- BusinessWire - BZX
Earnings Forecast Recap for Alibaba, Apple, Zynga, Gilead Sciences, Dendreon, and Juniper
8:45 a.m. Nov. 12, 2014
- PR Newswire - PRF
Gilead Announces Phase 2 Data for Investigational All-Oral Regimen of
Sofosbuvir Plus GS-5816 for the Treatment of Chronic Hepatitis C
8:02 a.m. Nov. 11, 2014
- BusinessWire - BZX
Gilead Announces Harvoni Study Results in Chronic Hepatitis C
Patients with Advanced Liver Disease and Those Who Failed Prior Treatment
8:02 a.m. Nov. 11, 2014
- BusinessWire - BZX
Earnings Forecast Buzz for Alibaba, Genworth Financial, Gilead Sciences, Zynga, Abercrombie & Fitch, and Plug Power
8:45 a.m. Nov. 10, 2014
- PR Newswire - PRF
Medifocus to Be Broadcast on BNN and Fox Business News on November
8th and 9th, 2014
10:56 a.m. Nov. 7, 2014
- Marketwired
(0)
(0)Scroll down for more posts ▼